GSK Q4 Results Climb; Sees Growth In FY26, Backs 2031 Sales View

GSK reported a strong Q4 with revenue up 6.2% to £8.618bn and profit before tax rising to £950m (from £563m a year ago); core pre-tax profit was £1.48bn and core attributable profit was £1.03bn (25.5p per share). The company issued 2026 guidance calling for 7–9% growth in core EPS and core operating profit and 3–5% turnover growth at constant exchange rates, reaffirmed a 2031 sales target of >£40bn, and raised the FY2025 dividend to 66p (Q4 18p) with an expected 2026 dividend of 70p. These results and upward guidance support continued commercial momentum in Specialty Medicines and increase shareholder returns, making the announcement material for equity investors evaluating GSK's growth and income profile.

Analysis

Market structure: GSK’s beat and 2026 guidance (core EPS +7–9%, turnover +3–5% cc) directly benefits GSK equity holders, specialty medicines suppliers and commercialization partners while increasing competitive pressure on peers with weaker specialty portfolios. Improved cashflow and a higher dividend (66p→expected 70p) should tighten GSK credit spreads and compress equity volatility; GBP could see modest support versus EUR/USD on sustained outperformance. The guidance implies accelerating demand for RI&I, oncology and HIV franchises and a relative shift of pricing power toward successfully launched specialty drugs over commoditized vaccines/generic-exposed products.

Risk assessment: Tail risks include a late-stage trial failure or major regulatory setback in the next 12–24 months, aggressive price controls in major markets, or an unexpected impairment that reverses margin expansion. Immediate (days) risk is an earnings re-rate; short-term (weeks–months) risk centers on launch execution and supply continuity; long-term (years) risk is achievement of the 2031 >£40bn target hinging on multiple launches. Hidden dependencies: execution depends on manufacturing scale-up and payer uptake—weakness there would materially reduce modeled EPS growth.

Trade implications: Establish a 2–3% long position in GSK (LSE:GSK) sized to portfolio risk for a 12–24 month horizon, adding on pullbacks of 5–10% or on sustained margin beat. Implement a relative-value pair: long GSK / short PFE (Pfizer) equal notional for 6–12 months to isolate specialty-execution upside; use a 12–18 month bull call spread (buy LEAP ~10% ITM, sell ~25% OTM) to cap cost. Collect dividend via covered-call overlays if owning stock; trim at +20–30% or if FY26 guidance falls below +5% core EPS growth.

Contrarian angles: Consensus may underprice launch execution risk—GSK’s stock can disappoint if launch uptake lags despite guidance, so upside is conditional not structural. The dividend increase is a double-edged sword: supports income buyers but may constrain M&A/R&D optionality needed to hit 2031 targets. Historically, large pharma re-ratings require several consistent quarters of above-consensus commercial execution; treat this as a staged buy with event-based scaling (trial readouts, payer wins) rather than a one-off buy-and-hold.

Key Decisions for Investors

• Establish a 2–3% long position in GSK (LSE:GSK) for a 12–24 month horizon; scale in on any 5–10% pullback post-earnings and target a 20–30% total return, set a hard stop-loss at 12% from entry.
• Put on a relative-value pair: long GSK (equal notional) / short PFE (Pfizer) for 6–12 months to isolate specialty execution upside; reduce exposure if GSK core EPS guidance drops below 5% for FY26.
• Buy a 12–18 month bull call spread on GSK (buy ~10% ITM LEAP, sell ~25% OTM) sized at 1% portfolio risk to capture upside while limiting premium outlay; roll or convert to stock if rollout metrics beat expectations at 6–12 months.
• If initiating stock ownership, sell covered calls across the next ex-dividend date to capture the 2026 expected dividend (70p) and aim to harvest 2–4% additional yield; unwind if share price appreciates >25% or on adverse guidance revisions.
• Monitor three high-impact triggers over the next 6–18 months before increasing conviction: (1) commercial uptake metrics for new RI&I/oncology launches (quarterly sales >consensus by 5–10%), (2) any late-stage trial readouts or regulatory approvals, and (3) changes in UK/EU/US pricing regulation; add only on positive read-throughs.